Effect of medicinal syrup made from silkworm cocoon on mixed anxiety-depression disorder: A triple-blind randomized clinical trial


Bombyx mori

How to Cite

Zeinalpour, Y., Kabiri, M. ., Rahimi, R. ., khalilzadeh, R., & Karimi, M. . (2021). Effect of medicinal syrup made from silkworm cocoon on mixed anxiety-depression disorder: A triple-blind randomized clinical trial. Iranian Red Crescent Medical Journal, 23(12). https://doi.org/10.32592/ircmj.2021.23.12.1345


OBJECTIVE: Silkworm cocoon produced by silkworms with the scientific name of Bombyx mori L. is a well-known medicinal agent mainly composed of proteins. This study was designed to assess the efficacy of syrup made from this natural agent on mild to moderate depression.

METHODS: The study was conducted based on a triple-blind randomized clinical trial. A total of 60 patients with mixed anxiety-depressive disorder were randomized to receive either intervention (silk syrup + sertraline) or control (placebo syrup + sertraline) for 12 weeks. Depression and anxiety were assessed using the Beck Depression and Anxiety inventories at weeks 0, 6, and 12.

RESULTS: Out of the subjects, 54 patients completed the trial in two groups of intervention (n=30) and control (n=24) and entered the final analysis. According to the results of this study, the mean of anxiety and depression scores in weeks 6 and week 12 was significantly lower in the intervention group than in the control group (P<0.001).

CONCLUSION: Silk syrup can be beneficial for the management of anxiety and depression in mild to moderate MADD; therefore, it is suggested as an adjuvant treatment to increase the efficacy of conventional medications adopted for the treatment of MADD patients.



  1. Balestrieri M, Isola M, Quartaroli M, Roncolato M, Bellantuono C. Assessing mixed anxiety-depressive disorder. A national primary care survey. Psychiatry Res. 2010;176(2-3):197-201. doi: 10.1016/j.psychres.2008.11.011 . [PubMed: 20129676].
  2. Organization WH. International statistical classification of diseases and related health problems: 10th revision (ICD-10); 1992.
  3. Merino H, Senra C, Ferreiro F. Are worry and rumination specific pathways linking neuroticism and symptoms of anxiety and depression in patients with generalized anxiety disorder, major depressive disorder and mixed anxiety-depressive disorder? PloS One. 2016;11(5):e0156169. doi: 10.1371/journal.pone.0156169. [PubMed: 27243462].
  4. Möller H-J, Bandelow B, Volz H-P, Barnikol UB, Seifritz E, Kasper S, et al. The relevance of ‘mixed anxiety and depression’as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci . 2016;266(8):725-36. doi: 10.1007/s00406-016-0684-7 . [PubMed: 27002521].
  5. Mairesse J, Van Camp G, Gatta E, Marrocco J, Reynaert ML, Consolazione M, et al. Sleep in prenatally restraint stressed rats, a model of mixed anxiety-depressive disorder.  Adv Neurobiol.  2015;10:27-44. doi: 10.1007/978-1-4939-1372-5_2 .  [PubMed: 25287534].
  6. Tsay S-L, Chen M-L. Acupressure and quality of sleep in patients with end-stage renal disease—a randomized controlled trial. Int J Nurs Stud. 2003;40(1):1-7. doi: 10.1016/s0020-7489(02)00019-6 . [PubMed: 12550145].
  7. Afsar B, Kirkpantur A. Are there any seasonal changes of cognitive impairment, depression, sleep disorders and quality of life in hemodialysis patients?. Gen Hosp Psychiatry. 2013;35(1):28-32. doi: 10.1016/j.genhosppsych.2012.08.007 . [PubMed: 23044242].
  8. Curcio G, Ferrara M, De Gennaro L. Sleep loss, learning capacity and academic performance. Sleep Med Rev. 2006;10(5):323-37. doi: 10.1016/j.smrv.2005.11.001 . [PubMed: 16564189].
  9. Boffa JW, Stanley IH, Smith LJ, et al. Posttraumatic Stress Disorder Symptoms and Suicide Risk in Male Firefighters: The Mediating Role of Anxiety Sensitivity. J Nerv Ment Dis. 2018;206(3):179-186. doi: 10.1097/NMD.0000000000000779 . [PubMed: 29309295].
  10. Nouwen A, Winkley K, Twisk J, Lloyd C E , M. Peyrot,5,6 K. Ismail,2 F. Pouwere t al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia; 2010;53(12):2480-6. doi: 10.1007/s00125-010-1874-x. [PubMed: 20711716].
  11. Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am. 2009;32(3):483-524. doi: 10.1016/j.psc.2009.06.002 . [PubMed: 19716988].
  12. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82(6):355-62. doi: 10.1159/000353198. [PubMed: 24061211].
  13. van Reedt Dortland AK, Giltay EJ, Van Veen T, Zitman FG, Penninx BW. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand. 2010;122(1):30-9. doi: 10.1111/j.1600-0447.2010.01565.x . [PubMed: 20456284].
  14. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM, et al. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67(11):1067-74. doi: 10.1016/j.biopsych.2009.12.012. [PubMed: 20138254].
  15. Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513-20. doi: 10.1097/NMD.0000000000000113 . [PubMed: 24594678].
  16. Avicenna H. Al-Qanon fi al-Tibb (Canon on medicine.), vol. 2. Beirut Lebanon: Alalami Library Publication; 2005.
  17. Mentang F, Maita M, Ushio H, Ohshima T. Efficacy of silkworm (Bombyx mori L.) chrysalis oil as a lipid source in adult Wistar rats. Food Chem. 2011;127(3):899-904. doi: 10.1016/j.foodchem.2011.01.045. [PubMed: 25214076].
  18. Ali MM, Arumugam SBA. Effect of crude extract of Bombyx mori coccoons in hyperlipidemia and atherosclerosis. J Ayurveda Integr Med. 2011;2(2):72-8. doi: 10.4103/0975-9476.82527 . [PubMed: 21760692].
  19. Young SN. Folate and depression—a neglected problem. J Psychiatry Neurosci. 2007;32(2):80-82. [PubMed: 17353937].
  20. Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viinamäki H, et al. Fish consumption, depression, and suicidality in a general population. Arch GenPsychiatry. 2001;58(5):512-3. doi: 10.1001/archpsyc.58.5.512. [PubMed: 11343534].
  21. Khan MS, Singh M, Khan MA, Arya D, Ahmad S. Scientific validation of cardioprotective attribute by standardized extract of Bombyx mori against doxorubicin-induced cardiotoxicity in murine model. EXCLI J. 2014;13:1043-54. [PubMed: 26417320].
  22. Waterborg JH. The Lowry method for protein quantitation. The protein protocols handbook, Springer; 2009.
  23. Julian LJ. Measures of anxiety: State‐Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale‐Anxiety (HADS‐A). Arthritis Care Res. 2011;
    63(011):S467-72. doi: 10.1002/acr.20561. [PubMed: 22588767].
  24. Wang Y-P, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013;35(4):416-31. doi: 10.1590/1516-4446-2012-1048 . [PubMed: 24402217].
  25. Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken).2011;63(11):S467-S72. doi: 10.1002/acr.20561. [PubMed: 22588767].
  26. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory - Second edition: BDI-II-PERSIAN. Depress Anxiety. 2005;21(4):185-92. doi: 10.1002/da.20070 . [PubMed: 16075452].
  27. Hossein Kaviani H, Mousavi A S. Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran Univ Med J. 2008;66(2):136-40.
  28. Amuli SH. Al-Mohit al-azam. Qom: Noor Ali Noor; 1422.
  29. Kendler KS, Gardner CO, Gatz M, Pedersen NL. The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med. 2007;37(3):453-62. doi: 10.1017/S0033291706009135. [PubMed: 17121688].
  30. Beesdo K, Pine DS, Lieb R, Wittchen H-U. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010;67(1):47-57. doi: 10.1001/archgenpsychiatry.2009.177 [PubMed: 20048222].
  31. Mahmood T, Siddiqui HH, Dixit R, Bagga P, Hussain S. Protective effect of Bombyx mori l cocoon (abresham) and its formulations against isoproterenol-induced cardiac damage. Trop J Pharm Res. 2015;14(1): 63-72. doi: 10.4314/tjpr.v14i1.10.
  32. Wattanathorn J, Muchimapura S, Boosel A, Sombat Kongpa. Silkworm Pupae Protects Against Alzheimer's Disease. Am J Agric Biol Sci. 2012;7(3):330-36. doi: 10.3844/ajabssp.2012.330.336.
  33. Maurizi C. The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging. Med Hypotheses. 1990;31(3):233-42. doi: 10.1016/0306-9877(90)90097-x. [PubMed: 2345536].
  34. Singh K, Jayasomu R. Bombyx mori–a review of its potential as a medicinal insect. Pharm Biol. 2002;40(1):28-32. doi: 10.1076/phbi.
  35. Reinke J, Sorg H. Wound repair and regeneration. Eur Surg Res. 2012;49(1):35-43. doi: 10.1159/000339613. [PubMed: 22797712].
  36. Rao TS, Asha M, Ramesh B, Rao KJ. Understanding nutrition, depression and mental illnesses. Indian J Psychiatry. 2008;50(2):77-82. doi: 10.4103/0019-5545.42391. [PubMed: 19742217].
  37. Yang H-J, Lee J-W, Lee S-H, Ryu SJ, Kwak DH, Nam KS, Park YI, Lee YC, Jung KY, Choo YK, et al. Estrogenic activity produced by aqueous extracts of silkworm (Bombyx mori) pupae in ovariectomized rats. Am J Chin Med. 2010;38(1):89-97. doi: 10.1142/S0192415X10007683 . [PubMed: 20128047].
  38. Hirose A, Terauchi M, Akiyoshi M, Owa Y, Kato K, Kubota T, et al. Depressive symptoms are associated with oxidative stress in middle-aged women: a cross-sectional study. Biopsychosoc Med. 2016;10(1):12. doi: 10.1186/s13030-016-0066-4. [PubMed:27118992].
  39. Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, Rhodes CJ, Valko M, et al. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011;31(2):95-107. doi: 10.1002/jat.1649 . [PubMed: 21321970].
  40. Poljsak B, Šuput D, Milisav I. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev. 2013;2013:1-11. doi: 10.1155/2013/956792 . [PubMed: 23738047].